Phreesia, Inc. (NYSE:PHR) CFO Sells $81,421.50 in Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 3,502 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total value of $81,421.50. Following the completion of the sale, the chief financial officer now directly owns 98,578 shares in the company, valued at approximately $2,291,938.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, July 16th, Balaji Gandhi sold 783 shares of Phreesia stock. The stock was sold at an average price of $23.74, for a total value of $18,588.42.

Phreesia Price Performance

PHR stock traded up $0.44 during trading hours on Thursday, hitting $23.76. 402,091 shares of the stock traded hands, compared to its average volume of 467,574. The stock has a 50-day simple moving average of $23.56 and a 200 day simple moving average of $22.75. The company has a market cap of $1.36 billion, a P/E ratio of -10.95 and a beta of 0.93. Phreesia, Inc. has a one year low of $12.05 and a one year high of $29.16. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Monday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $34.00 price target on shares of Phreesia in a report on Thursday, September 5th. DA Davidson reissued a “buy” rating and issued a $32.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Robert W. Baird raised their target price on Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Friday, September 6th. Finally, KeyCorp reduced their price target on Phreesia from $27.00 to $25.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Phreesia has an average rating of “Moderate Buy” and a consensus target price of $30.23.

Institutional Investors Weigh In On Phreesia

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of Phreesia by 4.4% in the 4th quarter. Vanguard Group Inc. now owns 4,628,441 shares of the company’s stock worth $107,148,000 after purchasing an additional 194,035 shares in the last quarter. Brown Advisory Inc. increased its holdings in shares of Phreesia by 22.2% in the fourth quarter. Brown Advisory Inc. now owns 3,950,356 shares of the company’s stock valued at $91,451,000 after buying an additional 716,374 shares in the last quarter. Capital International Investors lifted its position in shares of Phreesia by 221.1% during the 1st quarter. Capital International Investors now owns 2,593,063 shares of the company’s stock valued at $62,052,000 after acquiring an additional 1,785,463 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of Phreesia by 15.0% during the 4th quarter. Franklin Resources Inc. now owns 1,484,663 shares of the company’s stock worth $34,370,000 after acquiring an additional 193,480 shares in the last quarter. Finally, Champlain Investment Partners LLC acquired a new position in shares of Phreesia in the 1st quarter worth $29,941,000. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.